Drug Study of Albuterol to Treat Acute Lung Injury
Information source: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Respiratory Distress Syndrome, Adult
Intervention: Albuterol Sulfate (Drug); Mini-Bronchoalveolar Lavage (BAL) (Procedure); Placebo (Drug)
Phase: Phase 2/Phase 3
Status: Terminated
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI) Official(s) and/or principal investigator(s): Michael A. Matthay, MD, Principal Investigator, Affiliation: University of California, San Francisco Roy Brower, MD, Study Chair, Affiliation: Johns Hopkins University
Summary
Acute Respiratory Distress Syndrome (ARDS) and a lesser condition that occurs prior to ARDS,
Acute Lung Injury (ALI), are medical conditions that occur when there is severe inflammation
and increased fluids (edema) in both lungs, making it hard for the lungs to function
properly. Patients with these conditions require treatment that includes the use of a
breathing machine (ventilator). The purpose of this study is to find out whether giving
albuterol (a drug commonly used in asthmatics) or not giving albuterol to patients with ALI
or ARDS makes a difference in how long it takes for a patient to be able to breath without
the ventilator.
Clinical Details
Official title: Prospective, Randomized, Multicenter Trial of Aerosolized Albuterol Versus Placebo in Acute Lung Injury
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Number of Ventilator Free Days (VFD)
Secondary outcome: Mortality Prior to Hospital Discharge With Unassisted Breathing to Day 60Mortality Prior to Hospital Discharge With Unassisted Breathing to Day 90 Number of ICU-free Days at 28 Days After Randomization Number of Organ Failure-free Days at Day 28 Following Randomization Ventilator Free Days to Day 28 in the Subset of Participants With ARDS Hospital Mortality to Day 60 in the Subset of Participants With ARDS Ventilator Free Days to Day 28 in the Subset of Patients With Baseline Shock Hospital Mortality up to Day 60 in Subjects With Baseline Shock Plasma Levels of IL-6 and IL-8 on Study Day 3
Detailed description:
Aerosolized beta-2 agonist therapy is anticipated to diminish the formation of lung edema,
enhance clearance of lung edema and decrease pulmonary inflammation in patients with acute
lung injury. Because beta-2 agonists have been shown to reduce permeability induced lung
injury, it is anticipated that the severity of lung injury will be reduced by aerosolized
beta-2 agonist therapy. The therapy may work by enhancing resolution of pulmonary edema by
upregulating alveolar epithelial fluid transport mechanisms that will in turn enhance the
clearance of alveolar edema. A reduction in the severity of lung injury and the quantity of
alveolar edema should result in earlier extubation and more ventilator free days, improved
pulmonary oxygen uptake, and improved lung compliance.
Study design: phase II/III prospective, randomized double-blind, placebo controlled trial.
- In Phase II, patients will be treated with aerosolized albuterol 5. 0 mg vs. normal
saline (n=40-50)administered every 4 hours for 10 days following randomization or until
24 hours following extubation, whichever occurs first. The protocol stipulates that the
5. 0 mg dose will be reduced to 2. 5 mg if patients exceed defined heart rate limits.
- In Phase III, the 5. 0 mg dose will be used unless there is evidence that this dose has
an unacceptable safety profile or dose reductions for tachycardia occur in a large
fraction of patients. In that case, a lower dose of 2. 5 mg will be used.
- Patients will be followed for 90 days or until discharge from the hospital to home with
unassisted breathing whichever occurs first.
Eligibility
Minimum age: 13 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Must meet the following three criteria within a 24-hour period:
1. Acute onset of PaO2/FiO2 less than or equal to 300 (adjustments made for
altitude where appropriate)
2. Bilateral infiltrates consistent with pulmonary edema on frontal chest
radiograph
3. Requirement for positive pressure ventilation via endotracheal tube
- No clinical evidence of left-sided cardiac failure to account for bilateral pulmonary
infiltrates
Exclusion Criteria:
- Greater than 48 hours since all inclusion criteria are met
- Neuromuscular disease that impairs ability to ventilate without assistance, (e. g.,
cervical spinal cord injury at level C5 or higher spinal cord injury amyotrophic
lateral sclerosis, Guillain-Barré syndrome or myasthenia gravis)
- Pregnant or breast-feeding
- Severe chronic respiratory disease (i. e., chronic hypercapnia [PaCO2 greater than 45
mmHg], chronic hypoxemia [PaO2 less than 55 mmHg on FiO2 = 0. 21], hospitalization
within the last 6 months for respiratory failure [PaCO2 greater than 50 mm Hg and/or
PaO2 less than 55 mmHg on 0. 21 FiO2], secondary polycythemia, severe pulmonary
hypertension [mean PAP (pulmonary artery pressure) greater than 40 mmHg], or
ventilator dependency)
- Burns over greater than 40% of total body surface area
- Cancer or other irreversible disease or condition for which 6-month mortality is
estimated to be greater than 50%
- Allogeneic bone marrow transplant within the 5 years prior to study entry
- Participant, surrogate, or physician is not committed to full support (Exception: a
participant will not be excluded if he/she would receive all supportive care except
for attempts at resuscitation from cardiac arrest)
- Severe chronic liver disease (Child-Pugh score of 11-15)
- Diffuse alveolar hemorrhage from vasculitis
- Morbid obesity (greater than 1kg/cm body weight.)
- Unwillingness or inability to utilize the ARDS network 6 ml / kg Predicted Body
Weight (PBW) ventilation protocol
- Moribund participant and is not expected to survive 24 hours
- No intent to obtain central venous access for monitoring intravascular pressures
- Contraindication to aerosolized albuterol (see Appendix A. 8 of the protocol for more
information)
- Daily use (prior to study hospitalization) of inhaled beta agonist, corticosteroid,
or oral leukotriene modifier
- Unwillingness of primary physician to discontinue inpatient beta agonist use
- Acute myocardial infarction or acute coronary syndrome within 30 days of study entry
- Severe congestive heart failure (see Appendix A5 of the protocol for more
information)
- Participation in other experimental medication trial within 30 days of study entry
with the exception of the ARDSNet pharmaconutrient nutrition trial (OMEGA)
- Heart rate greater than 85% of maximal predicted heart rate (MHR85) as calculated by
MHR85 = 85% x (220-age)
- Currently receiving high frequency ventilation
Locations and Contacts
University of San Francisco-Fresno Medical Center, Fresno, California, United States
University of California, Davis Medical Center, Sacramento, California, United States
UCSF-Moffitt Hospital, San Francisco, California, United States
UCSF-San Francisco General Hospital, San Francisco, California, United States
Centura St. Anthony Central Hospital, Denver, Colorado, United States
Denver Health Medical Center, Denver, Colorado, United States
Rose Medical Center, Denver, Colorado, United States
University of Colorado Health Sciences Center, Denver, Colorado, United States
Washington Hospital Center, Washington DC, District of Columbia, United States
Baton Rouge General Hospital-Blue Bonnet, Baton Rouge, Louisiana, United States
Baton Rouge General Hospital-Midcity, Baton Rouge, Louisiana, United States
Earl K. Long Medical Center, Baton Rouge, Louisiana, United States
Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States
Medical Center of Louisiana, New Orleans, Louisiana, United States
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Tulane University Health Sciences Center, New Orleans, Louisiana, United States
Baltimore VA Medical Center, Baltimore, Maryland, United States
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Johns Hopkins Hospital, Baltimore, Maryland, United States
University of Maryland Shock Trauma Center, Baltimore, Maryland, United States
Baystate Medical Center, Springfield, Massachusetts, United States
Rochester Methodist Hospital, Rochester, Minnesota, United States
St. Mary's Hospital, Mayo Clinic, Rochester, Minnesota, United States
University of North Carolina, Chapel Hill, North Carolina, United States
Duke University Medical Center, Durham, North Carolina, United States
Durham Regional Medical Center, Durham, North Carolina, United States
Moses Cone Health System, Greensboro, North Carolina, United States
Wesley Long Community Hospital, Greensboro, North Carolina, United States
Wake Forest University Baptist Medical Center, Winston Salem, North Carolina, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
MetroHealth Medical Center, Cleveland, Ohio, United States
University Hospitals of Cleveland, Cleveland, Ohio, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Baylor College of Medicine, Houston, Texas, United States
McKay-Dee Hospital, Ogden, Utah, United States
Utah Valley Regional Medical Center, Provo, Utah, United States
LDS Hospital, Salt Lake City, Utah, United States
University of Virginia Medical Center, Charlottesville, Virginia, United States
Harborview Medical Center, Seattle, Washington, United States
University of Washington, Seattle, Washington, United States
Additional Information
NHLBI Acute Respiratory Distress Syndrome Network Website
Starting date: August 2007
Last updated: June 7, 2013
|